Home >
AEPSO Argentina launches digital map to find people with psoriasis in the country
2015/04/09 - News from patients associations
Psoriasis, recognised today by the World Health Organization (WHO) as a painful and incapacitating non communicable chronic disease, affects more than 800 000 Argentineans. AEPSO (Asociación Civil para el Enfermo de Psoriasis) celebrates its 10th anniversary raising awareness and supporting the rights of the patients. In order to better know what is going on with the disease in Argentina and to reach out the different communities, AEPSO has launched an interactive digital map, accessible through Facebook, that aims to identify and connect all psoriasis patients in each corner of the country.
Silvia Fernández Barrio, president and founder of AEPSO, has acknowledged that social networks have contributed to show unknown realities that they wish to work on for the benefit of the patients: “This is why this map came about, a tool that will give precise information where persons with psoriasis in Argentina live, and thus better help each one of them, guide them to informed professionals and to centres where they can get the treatment they need, as well as to create ties among patients going through the same experience in their community. In a territory as vast and with different realities we have to take advantage of technology as an opportunity to shorten distance and time”.
During the next 10 years, Beatriz Larrea, Executive Director of AEPSO, said that “we would like to achieve a presence of groups of people with psoriasis in every region of the country. That there are patients gathering, giving their time and sharing their experiences and knowledge in order to help others to better cope with their reality”.
One of the greatest obstacles that a psoriasis patients still faces is ignorance. There are patients that do not see a doctor because of the old prejudice that this is a disease that there is nothing you can do, so they give up. “Nothing could be farther from the truth”, exclaimed Silvia Fernández Barrio, adding “those people we must reach them through AEPSO; so that they know who we are, that we are here to help them, guide them, provide them with information and suggest where they can start to treat themselves. Their life can change, and is going to change”.
“We strive to achieve that no patient across the country lives withouth diagnosis or treatment; we have a lot of work ahead of us, but we know this is the way”, added the president of AEPSO.
You can find the map at:
https://www.facebook.com/pages/AEPSO/103448854973?sk=app_1497274527196166
SPIN Presentation
Recent news
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
- 2019/04/17 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P et al.
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat.
2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)
see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
Vasconcelos V et al.
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat.
2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)
see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep..
2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)
see on pubmed
on Atopic Dermatitis
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat.
2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)
see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
Choi EJ et al.
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem.
2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)
see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol.
2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)
see on pubmed
